| Skeletal Involvement |
| This page was written by Shelley Ensz, and has not yet been medically edited. Scleroderma (SD) affects everyone differently. Just because something is listed here does not mean an individual patient will ever experience it. See Disclaimer. |
|
|
| Osteoporosis in Scleroderma |
|
| Overview |
| Osteoporosis occurs when the rate of bone resorption exceeds the rate of bone formation creating "porous bones." Most cases of osteoporosis occur as an acceleration of this normal aging process. The condition can also be caused by other disease processes or prolonged use of certain medications that result in bone loss. Answers.com. (Also see: Bone Resorption) |
| Acid Reflux Drugs May Up Fractures. Using acid reflux drugs called proton pump inhibitors for at least seven years may be linked to increased risk of osteoporosis-related fractures. WebMD. 08/11/08. (Also see: Reflux) |
| Medical steroid's baffling connection to osteoporosis becomes clearer. Researchers have now identified osteoclasts, cells that dismantle old bone, as the essential link between osteoporosis and cortisone. EurekAlert! Washington University School of Medicine. 07/27/06. (Also see: Medications) |
| Osteoporosis and Scleroderma |
| Osteoporosis in scleroderma. Earlier menopause, corticosteroid use in some patients, and other factors secondary to systemic sclerosis (such as malabsorption and inflammation), may be causal factors or may be confounders in studies of osteoporosis (OP) in systemic sclerosis (SSc). PubMed. Semin Arthritis Rheum. 2005 Feb;34(4):678-82. |
| Relationship between capillaroscopic alterations and bone ultrasound parameters in patients with Raynaud phenomenon (RP). Our study suggest that RP, primarily in patients with scleroderma, modify phalangeal bone mass, bone density, and bone quality with a good correlation between nailfold patterns and quantitative ultrasound, independently from confounding variables. Alfredomaria Lurati, MD. The Internet Journal of Rheumatology. 2008. Vol 4 No 2. (Also see: Raynuad's) |
| Patients with Scleroderma (SSc) May Have Increased Risk of Osteoporosis. A Comparison to Rheumatoid Arthritis and Noninflammatory Musculoskeletal Conditions. Increasing the awareness to order bone mineral density measurements in patients with SSc may be warranted based on our results, especially for older patients. Sai Yan Yuen. J Rheumatol. April 15 2008. |
| Bone Mineral Density, Markers Of Bone Metabolism And Vitamin D Metabolites In Patients With Systemic Sclerosis (SSc). A osteologic screening should be done routinely in patients with SSc to prevent loss of bone mass by early, adequate osteoprotective medication. L. Philipp THU0303 EULAR 2007. (Also see: Vitamin D Dificiency) |
| Prognostic factors of low bone mineral density in systemic sclerosis. BMD results in fertile and postmenopausal SSc patients were independent of the SSc clinical variants, race and previous use of corticosteroids and cyclophosphamide. A low BMD in appendicular sites was observed in fertile and postmenopausal SSc patients when compared to a control healthy group, associated to a low BMI (bone mass index). PubMed. Clin Exp Rheumatol. 2005 Mar-Apr;23(2):180-4. |
| Vertebral Fracture and Bone Mineral Density in Women Receiving High Dose Glucocorticoids for Treatment of Autoimmune Diseases. The pathology of vertebral fracture secondary to high dose glucocorticoid therapy is multifactorial and possibly involves lipid metabolism. J Rheumatol 2005 May;32:863-9. (Also see: Medications) |
| Low Lean Body Mass is Associated with Osteoporosis in Systemic Sclerosis (SSc). This data, evaluating SSc patients in absence of important confounding variables that interfere with bone metabolism, show that SSc patients have a higher frequency of osteoporosis. The low lean mass and the high frequency of hypoalbuminemia in these patients emphasize the need for a nutrition orientation and a physical activity program as appropriate additional therapeutic measures to reduce bone loss in SSc patients. Romy B. Christmann. 1688/511. ACR 2004. |
| Bone Mineral Density in Female Patients with Systemic Sclerosis. The specific immunopathogenesis, the disease duration and activity, early menopause and a long-time immobilisation could be the reasons for increased bone resorption in the systemic sclerosis. Our study has confirmed statistically significant decrease of bone mineral density in scleroderma. B. N. Stamenkovic. FRI0306 EULAR 2004. |
| Clinical determinants of bone mass and bone ultrasonometry in patients with systemic sclerosis. SSc patients had reduced BMD (Bone Mineral Density) and SI (Stiffness Index) that was more marked in the diffuse form and in those with internal organ involvement and that became more marked with age and estrogen deficiency. This demineralisation was not related to the inflammation indices, disease duration, or to the immunological pattern. PubMed. Clin Exp Rheumatol. 2004 May-Jun;22(3):313-8. |
| Bone Density and HLA Antigens in Patients with Progressive Systemic Sclerosis. Mineral bone density is effectively reduced in PSS patients and this study confirms the above mentioned analysis; furthermore this study suggest that HLA class I may play an important role in the pathogenesis of PSS, since HLA-B18 is markedly increased in PSS patients compared to the healthy population. M. D'Amore. FRI0083 EULAR 2003. |
| Treatments for Osteoporosis |
| Osteoporosis Treatments and Care. Osteoporosis treatments come in several forms. Many should be started during childhood; others include prescription drugs to treat osteoporosis. Get an overview. WebMD. |
| Esophageal cancer linked to osteoporosis drugs. Merck's popular osteoporosis drug Fosamax and other similar drugs may carry a risk for esophageal cancer. The FDA also recommends that doctors should avoid prescribing the drugs to people with Barrett's esophagus, which is a change in the lining that leads to the stomach. NewsDaily. 12/31/08. (Also see: Barrett's Esophagus) |
| Combination Therapy Using Exercise and Pharmaceutical Agents to Optimize Bone Health. To reduce the individual and societal cost of osteoporosis there is a need for efficacious interventions. Two frequently prescribed interventions are load-bearing exercise and pharmaceutical agents. R. K. Fuchs. (SpringerLink) Clinical Reviews in Bone and Mineral Metabolism. June 14 2008. |
| Alfacalcidol Versus Plain Vitamin D in the Treatment of Glucocorticoid/ Inflammation-Induced Osteoporosis. Alfacalcidol plus calcium is highly superior to plain vitamin D3 plus calcium in the treatment of established GC (glucocorticoid) induced osteoporosis, and the latter should no longer be used as monotherapy. J Rheumatol 2005 September;32 Suppl 76:33-40. (Also see: Medications: Glucocorticoid) |
| Media Stories on Osteoporosis |
| Injectable artificial bone developed. Artificial 'injectable bone' that flows like toothpaste, and hardens in the body. This new regenerative medicine technology provides a scaffold for the formation of blood vessels and bone tissue, and can also deliver stem cells directly to the site of bone repair. J Goldenfein. Cosmos Online. 12/11/08. (Also see: Bone resoption) |
| Bisphosphonates Linked To Incapacitating Bone, Joint, and Muscle Pain - FDA Alerts The Food and Drug Administration (FDA) is reminding doctors of the link between taking bisphosphonates and a raised risk of experiencing often incapacitating bone, joint, and/or musculoskeletal pain. Medical News Today. 07 Jan 2008. (Also see: FDA Warnings) |
| Balance of Essential Fats May Prevent Bone Loss After Menopause. Diets with a high ratio of omega-6 fatty acids to omega-3 fatty acids are often associated with cardiovascular disease, cancer and inflammatory and autoimmune diseases. A low ratio of omega-6 to omega-3 fatty acids, however, is believed to promote cardiovascular health, improve memory and, as the current study shows, protect bone health. Newswise. 07/12/05. |
| Patient Stories |
| Susie: CREST Syndrome I have had CREST syndrome for the past eight years. My specialist is Dr. Frederick Wigley, from Johns Hopkins... |
